🧪 What It Is

• Active compound: Tirzepatide

• Class: Dual incretin receptor agonist (GIP + GLP-1)

• Form: Prefilled subcutaneous injection pen

• Strength: 50 mg total peptide per pen

Tirzepatide works by mimicking the actions of gut hormones that regulate glucose, appetite, and metabolism.

🧬 How It Works

Tirzepatide binds to two incretin receptors:

1. GLP-1 (glucagon-like peptide-1):

   • Stimulates insulin secretion

   • Slows gastric emptying

   • Reduces appetite

2. GIP (glucose-dependent insulinotropic polypeptide):

   • Enhances insulin release in response to meals

   • Improves metabolic efficiency

This combination leads to:

• Better blood sugar control

• Reduced appetite and caloric intake

• Potential weight loss

💡 Clinical Effects

In clinical trials and approved use, Tirzepatide is associated with:

• Significant HbA1c reduction in type 2 diabetes

• Marked body weight reduction

• Improved insulin sensitivity

• Possible improvement in lipid profiles

It is considered more potent for weight loss than single-pathway GLP-1 analogs like semaglutide.

💉 Pen Format

• Delivery: Subcutaneous injection

• Presentation: Prefilled pen with multiple doses

• Labeling: Tirzepatide, total content (50 mg), batch/lot info

• Administration: Weekly injections (dose titration may be required)

The pen ensures precise dosing and user-friendly self-administration.